Browse NCKAP1

Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass membrane protein Cytoplasmic side Cell projection, lamellipodium membrane Single-pass membrane protein Cytoplasmic side Note=At the interface between the lamellipodial actin meshwork and the membrane.
Domain PF09735 Membrane-associated apoptosis protein
Function

Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex. Actin remodeling activity is regulated by RAC1. As component of the WAVE1 complex, required for BDNF-NTRK2 endocytic trafficking and signaling from early endosomes.

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006909 phagocytosis
GO:0007015 actin filament organization
GO:0007265 Ras protein signal transduction
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010591 regulation of lamellipodium assembly
GO:0010592 positive regulation of lamellipodium assembly
GO:0016601 Rac protein signal transduction
GO:0030031 cell projection assembly
GO:0030032 lamellipodium assembly
GO:0030041 actin filament polymerization
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031334 positive regulation of protein complex assembly
GO:0031346 positive regulation of cell projection organization
GO:0032271 regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0034314 Arp2/3 complex-mediated actin nucleation
GO:0034315 regulation of Arp2/3 complex-mediated actin nucleation
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0045010 actin nucleation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0051125 regulation of actin nucleation
GO:0051127 positive regulation of actin nucleation
GO:0051258 protein polymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0060491 regulation of cell projection assembly
GO:0090066 regulation of anatomical structure size
GO:0097581 lamellipodium organization
GO:1902743 regulation of lamellipodium organization
GO:1902745 positive regulation of lamellipodium organization
GO:2000601 positive regulation of Arp2/3 complex-mediated actin nucleation
Molecular Function GO:0017016 Ras GTPase binding
GO:0017048 Rho GTPase binding
GO:0031267 small GTPase binding
GO:0048365 Rac GTPase binding
GO:0051020 GTPase binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030027 lamellipodium
GO:0030055 cell-substrate junction
GO:0031209 SCAR complex
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0031258 lamellipodium membrane
> KEGG and Reactome Pathway
 
KEGG hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663213: RHO GTPases Activate WASPs and WAVEs
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-194138: Signaling by VEGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NCKAP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NCKAP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.42; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NCKAP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0010.998
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0940.969
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0740.964
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3050.353
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3910.869
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.20.945
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0630.904
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2190.92
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1260.958
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0930.954
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7030.769
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0270.694
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NCKAP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NCKAP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NCKAP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NCKAP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NCKAP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NCKAP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NCKAP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNCKAP1
NameNCK-associated protein 1
Aliases HEM2; NAP125; p125Nap1; membrane-associated protein HEM-2; NAP 1
Chromosomal Location2q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NCKAP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.